Piramal Pharma unveils its Sustainability Report FY21–22

Piramal Pharma yesterday unveiled its Sustainability Report FY21–22 to provide a view of its performance on Environment, Social and Governance (ESG) parameters. The report highlights the company’s responsible growth aspirations through sustainable operations covering all three businesses – Contract Development and Manufacturing Organisation (CDMO), Complex Hospital Generics (CHG) and India Consumer Healthcare (ICH) across India, the United Kingdom (UK), and the United States (US), a statement from Piramal Pharma notified.

The report focusses on the company’s purpose and vision that underlies its ESG strategic and operational framework built on the four pillars of responsible operations, stakeholder centricity, business resilience, and quality and excellence.

Nandini Piramal, Executive Director, Piramal Enterprises, and Chairperson, Piramal Pharma, claimed in the statement, “Piramal has always prioritised sustainability practices at its core across all its operations. We have been taking significant steps in the areas of wastewater recycling and energy conservation, climate change management, increasing the diverse workforce, and continued high commitment towards our CSR initiatives in the areas of healthcare and education. This resonates with our corporate purpose of ‘Doing Well and Doing Good’……………”

Further, according to the statement, the report demonstrates Piramal Pharma’s intent of sharing its sustainability performance and targets with its stakeholders. Towards this, the company also responded to the CDP climate change and water security disclosures. In addition, the company is committed to achieve value chain-based sustainability by engaging with its customers and suppliers on various business aspects, including those related to ESG.

The key highlights of the report are as follows:

Environment

· Increased the use of renewable energy by replacing coal with bio-briquette, installing solar roof panels and using hydroelectric power

· Controlled emissions using process controls and technologies, including nitrogen blanketing, efficient gas scrubbing systems, multi-stage condensers, bag filters and electrostatic precipitators

· Implemented tree plantation programmes across locations; Piramal Pharma’s manufacturing facilities currently have more than 82,000 trees

· Drove technology absorption for energy efficiency and greenhouse gases reduction

Social

· 30 per cent female representatives on the Board of Directors

· 113 million beneficiaries impacted till date through CSR under Piramal Foundation

· Zero fatalities in FY21–22

· 7,834 hours devoted to Environment, Health and Safety (EHS) training in FY21–22

Governance

· Formed the Sustainability and Risk Management Committee, headed by the Chairperson, that guides the management on the sustainability endeavours

· Cleared 269 regulatory inspections and 1,377 customer audits since FY11–12 through FY21–22. Zero Official Actions Indicated (OAIs)

· Conducted a materiality assessment to identify key material aspects from ESG perspective and developed an ESG strategy framework

The company developed the ESG framework during FY21–22, which has 12 focus areas, guiding Piramal Pharma’s strategic and operational imperatives.